EUCTR2015-002619-14-BE进行中（未招募）1 期
INSTAGE (TM) : A 24-week, double-blind, randomized, parallel-group study evaluating the efficacy and safety of oral nintedanib coadministrated with oral sildenafil, compared to treatment with nintedanib alone, in patients with idiopathic pulmonary fibrosis (IPF) and advanced lung function impairment - INSTAGE (TM)
SCS Boehringer Ingelheim Comm. V0 个研究点目标入组 300 人开始时间: 2016年6月3日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Written informed consent consistent with ICH-GCP and local laws, signed prior to any study procedures being performed (including any required washout);
- •2. Male or female patients aged =40 years at visit 1;
- •3. A clinical diagnosis of IPF within the last 6 years before visit 1, based upon the ATS/ERS/JRS/ALAT 2011 guideline;
- •4. Combination of high-resolution computed tomography (HRCT) pattern, and if available, surgical lung biopsy pattern consistent with a diagnosis of IPF as assessed by the investigator based on a HRCT scan performed within 18 months of visit 1;
- •5. DLCO (corrected for Hb) = 35% predicted of normal at visit 1.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 50
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 200
排除标准
- •1. Previous enrolment in this trial;
- •2. ALT, AST > 1.5 fold upper limit of normal (ULN) at visit 1;
- •3. Total bilirubin > 1.5 fold ULN at visit 1;
- •4. Relevant airways obstruction (i.e. pre-bronchodilator FEV1/FVC <0.7 at visit 1);
- •5. History of myocardial infarction within 6 months of visit 1 or unstable angina within 1 month of visit 1;
- •6. Bleeding Risk: - Known genetic predisposition to bleeding; - Patients who require fibrinolysis, full-dose therapeutic anticoagulation (e.g. vitamin K antagonists, direct thrombin inhibitors, heparin, hirudin, etc.) or high dose antiplatelet therapy; - History of haemorrhagic central nervous system (CNS) event within 12 months prior to visit 1; - History of haemoptysis or haematuria, active gastro-intestinal bleeding or ulcers and/or major injury or surgery within 3 months prior to visit 1; - International normalised ratio (INR) > 2 at visit 1; - Prothrombin time (PT) and activated partial thromboplastin time (aPTT) > 150% of institutional ULN at visit 1;
- •7. Planned major surgery during the trial participation, including lung transplantation, major abdominal or major intestinal surgery;
- •8. History of thrombotic event (including stroke and transient ischemic attack) within 12 months of visit 1;
- •9. Creatinine clearance < 30 mL/min calculated by Cockcroft-Gault formula at visit 1;
- •10. Presence of aortic stenosis (AS) per investigator judgement at visit 1;
- •11. Severe chronic heart failure: defined by left ventricular ejection fraction (EF) < 25% per investigator judgement at visit 1;
- •12. Presence of idiopathic hypertrophic subaortic stenosis (IHSS) per investigator judgement at visit 1; 13. Second-degree or third-degree atrioventricular (AV) block on electrocardiogram (ECG) per investigator judgement at visit 1;
- •14. Hypotension (systolic blood pressure [SBP] < 100 mm Hg or diastolic blood pressure [DBP] < 50 mm Hg) (symptomatic orthostatic hypotension) at visit 1;
- •15. Uncontrolled systemic hypertension (SBP > 180 mmHg or DBP > 100 mmHg) at visit 1;
- •16. Known penile deformities or conditions (e.g., sickle cell anemia, multiple myeloma, leukemia) that may predispose to priapism;
- •17. Retinitis pigmentosa;
- •18. History of vision loss;
- •19. History of nonarteritic ischemic optic neuropathy;
- •20. Veno-occlusive disease;
- •21. History of acute IPF exacerbation or respiratory infection within 8 weeks of visit 2.
- •22. Treatment with nitrates, n-acetylcysteine, pirfenidone, azathioprine, cyclophosphamide, cyclosporine, prednisone >15 mg daily or >30 mg every 2 days OR equivalent dose of other oral corticosteroids as well as any investigational drug within 4 weeks of visit 2;
- •23. Treatment with prostaglandins (e.g., epoprostenol, treprostinil), endothelin-1 antagonists (e.g., bosentan, sitaxsentan, ambrisentan), phosphodiesterase inhibitors (e.g., sildenafil, tadalafil, vardenafil) or a stimulator of guanylatcyclase (e.g., riociguat) within 4 weeks of visit 2;
- •24. Treatment with potent CYP3A4 inhibitors such as ketoconazole, itraconazole and ritonavir within 4 weeks of visit 2;
- •25. Supplementation with L-arginine and concurrent use of grapefruit juice or St John's wort within 4 weeks of visit 2;
- •26. Treatment with the reduced dose of nintedanib (100 mg bid) within 4 weeks of visit 2;
- •27. Permanent discontinuation of nintedanib in the past due to adverse events considered drug-related;
- •28. Known hypersensitivity or intolerance to nintedanib, sildenafil, galactose, peanut or soy
研究者
相似试验
进行中（未招募）
1 期
Efficacy and safety of nintedanib when co-administered with sildenafil in IPF patients with advanced lung function impairmentpatients with idiopathic pulmonary fibrosis (IPF) and advanced lung function impairmentMedDRA version: 19.0Level: PTClassification code 10021240Term: Idiopathic pulmonary fibrosisSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2015-002619-14-DEBoehringer Ingelheim Pharma GmbH & Co. KG300
进行中（未招募）
1 期
Efficacy and safety of nintedanib when co-administered with sildenafil in IPF patients with advanced lung function impairmentEUCTR2015-002619-14-GBBoehringer Ingelheim Limited406
进行中（未招募）
1 期
Efficacy and safety of nintedanib when co-administered with sildenafil in IPF patients with advanced lung function impairmentpatients with idiopathic pulmonary fibrosis (IPF) and advanced lung function impairmentMedDRA version: 21.1Level: PTClassification code 10021240Term: Idiopathic pulmonary fibrosisSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2015-002619-14-ITBOEHRINGER-INGELHEIM ITALIA S.P.A.406
进行中（未招募）
不适用
Safety and Efficacy of mometasone furoate delivered via Breezhaler® or Twisthaler® in adult and adolescent patients with persistent asthmaMedDRA version: 14.1Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersAsthmaEUCTR2011-005100-14-NLovartis Pharma Services AG616
进行中（未招募）
1 期
Safety and Efficacy of mometasone furoate delivered via Concept1 or Twisthaler® in adult and adolescent patients with persistent asthmaMedDRA version: 14.1Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersAsthmaEUCTR2011-005100-14-BEovartis Pharma Services AG616